Modelling the lymphatic metastatic progression pathways of OPSCC from multi-institutional datasets
-
Published:2024-07-08
Issue:1
Volume:14
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Ludwig Roman,Schubert Adrian Daniel,Barbatei Dorothea,Bauwens Lauence,Hoffmann Jean-Marc,Werlen Sandrine,Elicin Olgun,Dettmer Matthias,Zrounba Philippe,Pouymayou Bertrand,Balermpas Panagiotis,Grégoire Vincent,Giger Roland,Unkelbach Jan
Abstract
AbstractThe elective clinical target volume (CTV-N) in oropharyngeal squamous cell carcinoma (OPSCC) is currently based mostly on the prevalence of lymph node metastases in different lymph node levels (LNLs) for a given primary tumor location. We present a probabilistic model for ipsilateral lymphatic spread that can quantify the microscopic nodal involvement risk based on an individual patient’s T-category and clinical involvement of LNLs at diagnosis. We extend a previously published hidden Markov model (HMM), which models the LNLs (I, II, III, IV, V, and VII) as hidden binary random variables (RVs). Each represents a patient’s true state of lymphatic involvement. Clinical involvement at diagnosis represents the observed binary RVs linked to the true state via sensitivity and specificity. The primary tumor and the hidden RVs are connected in a graph. Each edge represents the conditional probability of metastatic spread per abstract time-step, given disease at the edge’s starting node. To learn these probabilities, we draw Markov chain Monte Carlo samples from the likelihood of a dataset (686 OPSCC patients) from three institutions. We compute the model evidence using thermodynamic integration for different graphs to determine which describes the data best.The graph maximizing the model evidence connects the tumor to each LNL and the LNLs I through V in order. It predicts the risk of occult disease in level IV is below 5% if level III is clinically negative, and that the risk of occult disease in level V is below 5% except for advanced T-category (T3 and T4) patients with clinical involvement of levels II, III, and IV. The provided statistical model of nodal involvement in OPSCC patients trained on multi-institutional data may guide the design of clinical trials on volume-deescalated treatment of OPSCC and contribute to more personal guidelines on elective nodal treatment.
Funder
Swiss Cancer Research Foundation Universität Zürich
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Grégoire, V. et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC. RTOG Consensus Guidelines. Radiotherapy and Oncology 69, 227–236 (2003) (ISSN: 0167-8140). 2. Grégoire, V. et al. Delineation of the Neck Node Levels for Head and Neck Tumors: A 2013 Update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG. TROG Consensus Guidelines. Radiotherapy and Oncology 110, 172–181 (2014). 3. Grégoire, V. et al. Delineation of the Primary Tumour Clinical Target Volumes (CTV-P) in Laryngeal, Hypopharyngeal, Oropharyngeal and Oral Cavity Squamous Cell Carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO. TROG Consensus Guidelines. Radiother. Oncol. 126, 3–24 (2018). 4. Eisbruch, A., Foote, R. L., O’Sullivan, B., Beitler, J. J. & Vikram, B. Intensity-Modulated Radiation Therapy for Head and Neck Cancer: Emphasis on the Selection and Delineation of the Targets. Seminars in Radiation Oncology 12, 238–249 (2002) (ISSN: 1053-4296). 5. Biau, J. et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: A 2019 update. Radiotherapy and Oncology 134, 1–9 (2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|